- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT01253330
Usage, Usability & Effect on Adherence and Clinical Outcomes of Text Message Reminders for Adolescents With Asthma
11 février 2016 mis à jour par: Children's Hospital Medical Center, Cincinnati
Study of the Usage, Usability, Acceptability, and Effect on Adherence and Clinical Outcomes of a Web Based Text Messaging System for Adolescents With Asthma- Phase 2
The purpose of this randomized crossover study is to determine the efficacy of participant designed medication reminders on asthma control, asthma related quality of life,and medication adherence.
In addition, this study will provide data regarding the usage, usability, acceptability of an online system designed for creating text message reminders.
It is hypothesized that the teens receiving text message reminders will report having greater quality of life related to their asthma, a reported increase in the control of their asthma, and increased adherence to their medication regimen compared to those teens that are not receiving the text message reminders.
Aperçu de l'étude
Description détaillée
Adolescents are typically less adept at managing chronic illnesses and adhering to treatment plans than are parents of younger children.
Adolescents are also typically "early adopters" to technological solutions and text messages are integral in today's teen culture.
Text messages are gaining acceptance in health care both as appointment reminders and direct inquiries.
The purpose of this randomized crossover study is to examine the effect of participant designed medication reminders on asthma control, asthma related quality of life, and medication adherence.
In addition, this study will provide data regarding the usage, usability, and acceptability of an online system designed for creating text message reminders.
Type d'étude
Interventionnel
Inscription (Réel)
61
Phase
- N'est pas applicable
Contacts et emplacements
Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.
Lieux d'étude
-
-
Ohio
-
Cincinnati, Ohio, États-Unis, 45229
- Cincinnati Children's Hospital Medical Center
-
-
Critères de participation
Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.
Critère d'éligibilité
Âges éligibles pour étudier
12 ans à 22 ans (Enfant, Adulte)
Accepte les volontaires sains
Non
Sexes éligibles pour l'étude
Tout
La description
Inclusion Criteria:
- Between the ages of 12 and 22
- Diagnosis of Persistent Asthma
- Receiving care at Cincinnati Children's Hospital Medical Center or affiliate
- Prescription of a controller medication
- Must have a cell phone that receives text messages
- Asthma is not well-controlled based on ACT score
- English Speaking
Exclusion Criteria:
- No diagnosis of persistent asthma
- Receiving asthma care other than at a Cincinnati Children's Hospital Medical Center or affiliate
- Asthma is well-controlled based on ACT score
- Does not have a cell phone that receives text messages or plans to change phones within the next 6 months
- Is not taking a daily asthma controller medication
- Is currently receiving asthma appointment or medication reminder text messages from another source
Plan d'étude
Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Recherche sur les services de santé
- Répartition: Randomisé
- Modèle interventionnel: Affectation croisée
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Aucune intervention: Comparison 1st
Not enrolled in the CMSText website text messaging system during last 3 months of study participation.
|
|
|
Expérimental: Participant 1st
Enrollment in the CMSText website text messaging system during first 3 months of study participation.
|
During baseline (Participant 1st Arm) or Month 3 Visit (Comparison 1st Arm), the study staff member will demonstrate for the teen how to log-on to the calendar system and set up reminders.
Teens will be able to set their own reminders and add other reminders in addition to those that are asthma related.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Asthma Control Test (ACT)
Délai: Change from Baseline on ACT at 3 months (1st arm), Change from Baseline on ACT at 6 months (2nd arm)
|
The teen will complete the Asthma Control Test (ACT), a validated 5-item Likert scale test that asks them to detail their asthma symptoms.
These are questions consistent with those that would be asked by a clinician (i.e., how many times have you used your fast-acting inhaler in the past four weeks, how often does asthma limit your activities).
The responses to these questions will also be used to calculate the teen's asthma control.
|
Change from Baseline on ACT at 3 months (1st arm), Change from Baseline on ACT at 6 months (2nd arm)
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
The Pediatric Quality of Life Scale Version 4.0 Teen Report (ages 13- 18) (PedsQL)
Délai: Change from Baseline on PedsQL at 3 months (1st arm), Change from Baseline on PedsQL at 6 months (2nd arm)
|
This assessment measures how much asthma has been a problem for them in the last month (i.e., "It is hard for me to be responsible for my medications.",
"I worry about my asthma.")
|
Change from Baseline on PedsQL at 3 months (1st arm), Change from Baseline on PedsQL at 6 months (2nd arm)
|
|
Adherence
Délai: Change from Baseline in Adherence at 3 months (1st arm), Change from Baseline in Adherence at 6 months (2nd arm)
|
Adherence to medication regimen will be monitored with the Smartinhaler Tracker developed by Nexus 6 ltd.
It will record the adherence to medication administered through metered-dose inhalers, which include medication such as Qvar and Flovent.
The Smartinhaler records the time and date medications were taken, whether the canister was shaken appropriately prior to inhalation, and how much the medication was inhaled.
|
Change from Baseline in Adherence at 3 months (1st arm), Change from Baseline in Adherence at 6 months (2nd arm)
|
Collaborateurs et enquêteurs
C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.
Collaborateurs
Les enquêteurs
- Chercheur principal: Maria T Britto, M.D., M.P.H., Children's Hospital Medical Center, Cincinnati
Dates d'enregistrement des études
Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.
Dates principales de l'étude
Début de l'étude
1 novembre 2010
Achèvement primaire (Réel)
1 décembre 2012
Achèvement de l'étude (Réel)
1 décembre 2012
Dates d'inscription aux études
Première soumission
29 novembre 2010
Première soumission répondant aux critères de contrôle qualité
2 décembre 2010
Première publication (Estimation)
3 décembre 2010
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
12 février 2016
Dernière mise à jour soumise répondant aux critères de contrôle qualité
11 février 2016
Dernière vérification
1 février 2016
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 20090445
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .